SCHEMBL25758942

SCHEMBL25758942

COc1ccnc(C(=O)Nc2ccc(OC)c(S(=O)(=O)Nc3ccc(Cl)cc3)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
IDH1 O75874 5/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
HPGD P15428 1/20 0.57
HTT P42858 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 3/20 0.53
GAA P10253 3/20 0.53
TP53 P04637 1/20 0.53
ALDH1A1 P00352 1/20 0.50
ALOX12 P18054 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846582 0.87 LMNA (0.56) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23833728 0.83 LMNA (0.53) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL30199798 0.83 LMNA (0.53) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23846650 0.82 LMNA (0.54) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23846316 0.81 LMNA (0.58) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL7529463 0.80 TP53 (0.80) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23846615 0.78 MEN1 (0.52) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23846390 0.77 MAPT (0.62) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23846587 0.76 IDH1 (0.53) LMNAMEN1KMT2AIDH1SMN1; SMN2
SCHEMBL23833764 0.76 LMNA (0.52) LMNAMEN1KMT2AIDH1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 LMNA 3435/4885MEN1 3902/4885KMT2A 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.